An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.
Also called NCT01670981
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 114 participants
- Sponsor
- Vericel Corporation
- Registry
-
NCT01670981
-
- Other papers using this trial's data
- Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01670981. Randomized; quadruple masking; primary purpose treatment. Start 2013-02-20 (actual); primary completion 2016-02-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
- Acronym
- ixCELLDCM
- Condition
- Ischemic Dilated Cardiomyopathy (IDCM)
- Intervention (Biological)
- ixmyelocel-T
- Intervention (Other)
- Placebo
- Lead sponsor
- Vericel Corporation
Record details
- Record id
cardio:ct-nct01670981- Content hash
a753ef5ebb77da9dc13149174d3180cda5f7a4899c72b72831a75726920f0fb4